Osteopore (ASX:OSX) launched a clinical trial with Princess Alexandra Hospital for the reconstruction of jawbones in at least 10 adult patients, with the single-arm feasibility trial will be conducted in Australia, according to a Wednesday ASX filing.
It plans to determine the safety and tolerability of polycaprolactone-tricalcium phosphate scaffolds with a vascularized corticoperiosteal tissue transfer. The technique, applied with the polycaprolactone-tricalcium phosphate scaffolds, was previously successfully employed in previous cranial and long-bone reconstruction trials.
Patient recruitment for the maxillomandibular reconstruction trial is expected by 2028, and patient follow-up is expected to be 36 months post-surgery.
The Human Research and Ethics Committee at Metro South Health provided clearance, while the firm expects clearance from the Research Governance Office.
Its shares jumped 7% in recent trading on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。